Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S5 - E11.1 - How The Rezdiffra Approval Has Affected How One Clinic Manages MASH Patients
Description: In this initial conversation, Michael Charlton describes some ways that the presence of Rezdiffra has affected practices and procedures in his clinic and shares issues he and his colleagues are discussing. As the conversation begins, Michael hails Rezdiffra as proof that as a species, "we can be capable of amazing things in a good way," a drug approved by FDA to reverse fibrosis in a significant number of patients with the world's most common liver disease. From there, he goes on to discuss the challenges his metabolic live disease clinic faces in prescribing the drug. The first i...